Hosted on MSN58m
Royalty Pharma (NASDAQ:RPRX) Misses Q4 Revenue EstimatesHealthcare royalties company Royalty Pharma (NASDAQ:RPRX) in Q4 CY2024, with sales flat year on year at $594 million. Its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback